Oral Agents to Add to Tradjenta (Linagliptin) When SGLT2 Inhibitors Are Contraindicated

Primary Recommendation: GLP-1 Receptor Agonists

The American Diabetes Association and the European Association for the Study of Diabetes recommend adding a GLP-1 receptor agonist (liraglutide, dulaglutide, or semaglutide) to linagliptin for patients with type 2 diabetes, as these agents provide proven cardiovascular and renal benefits, significant HbA1c reduction (0.5-1.0%), weight loss, and low hypoglycemia risk when combined with DPP-4 inhibitors 1, 2
The 2022 KDIGO guideline specifically recommends GLP-1 RAs with proven cardiovascular disease benefits if SGLT2 inhibitors are not tolerated or contraindicated 1

GLP-1 RAs reduce the risk of myocardial infarction, stroke, and cardiovascular death in patients with established cardiovascular disease or multiple cardiovascular risk factors, according to the American College of Cardiology 1, 2
GLP-1 RAs reduce albuminuria and preserve estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy, as recommended by the National Kidney Foundation 3
GLP-1 RAs typically result in a weight loss of 1.5-3.5 kg, as reported by the American Heart Association 2
GLP-1 RAs have a low hypoglycemia risk due to their glucose-dependent mechanism, as stated by the Endocrine Society 2, 4

Liraglutide can be started at 0.6 mg subcutaneously once daily and increased to 1.2-1.8 mg after 1 week, with no renal dose adjustment needed, as recommended by the American Association of Clinical Endocrinologists 1
Dulaglutide can be started at 0.75 mg subcutaneously once weekly and increased to 1.5 mg weekly if needed, with no renal dose adjustment needed, as recommended by the European Association for the Study of Diabetes 1
Semaglutide can be started at 0.25 mg subcutaneously once weekly for 4 weeks, then 0.5 mg weekly, and increased to 1 mg weekly if needed, with no renal dose adjustment needed, as recommended by the American Diabetes Association 1

The American College of Cardiology recommends not adding another DPP-4 inhibitor (sitagliptin, saxagliptin, alogliptin) to linagliptin, as combining two drugs from the same class provides no additional benefit and is not recommended 4
The Endocrine Society recommends avoiding sulfonylureas (glyburide, glipizide) when possible due to significant hypoglycemia risk, weight gain, and lack of cardiovascular benefit 5